Page 54 - MI-1-1

Microbes & Immunity The feature of bladder cancer stem cells

100. Tsuchiya H, Shiota G. Immune evasion by cancer stem 110. Li C, Yan R, Yang Z, et al. BCMab1-Ra, a novel immunotoxin
cells. Regen Ther. 2021;17:20-33. that BCMab1 antibody coupled to Ricin A chain, can eliminate
bladder tumor. Oncotarget. 2017;8(28):46704-46705.
doi: 10.1016/j.reth.2021.02.006
doi: 10.18632/oncotarget.13504
101. Jinesh GG, Manyam GC, Mmeje CO, Baggerly KA,
Kamat AM. Surface PD-L1, E-cadherin, CD24, and 111. Wang T, Niu G, Kortylewski M, et al. Regulation of the
VEGFR2 as markers of epithelial cancer stem cells associated innate and adaptive immune responses by Stat-3 signaling
with rapid tumorigenesis. Sci Rep. 2017;7(1):9602. in tumor cells. Nat Med. 2004;10(1):48-54.
doi: 10.1038/s41598-017-08796-z doi: 10.1038/nm976
102. Liu S, Liu Z, Shang A, et al. CD44 is a potential 112. Gelain A, Mori M, Meneghetti F, Villa S. Signal transducer
immunotherapeutic target and affects macrophage and activator of transcription protein 3 (STAT3): An
infiltration leading to poor prognosis. Sci update on its direct inhibitors as promising anticancer
Rep. 2023;13(1):9657. agents. Curr Med Chem. 2019;26(27):5165-5206.
doi: 10.1038/s41598-023-33915-4 doi: 10.2174/0929867325666180719122729
103. Yao Y, Ye H, Qi Z, et al. B7-H4(B7x)-Mediated cross-talk 113. Jonker DJ, Nott L, Yoshino T, et al. Napabucasin versus
between glioma-initiating cells and macrophages via the placebo in refractory advanced colorectal cancer:
IL6/JAK/STAT3 pathway lead to poor prognosis in glioma A randomised phase 3 trial. Lancet Gastroenterol Hepatol.
patients. Clin Cancer Res. 2016;22(11):2778-2790. 2018;3(4):263-270.
doi: 10.1158/1078-0432.Ccr-15-0858 doi: 10.1016/s2468-1253(18)30009-8
104. Lee Y, Shin JH, Longmire M, et al. CD44+ cells in 114. Zou S, Tong Q, Liu B, Huang W, Tian Y, Fu X. Targeting
head and neck squamous cell carcinoma suppress STAT3 in cancer immunotherapy. Mol Cancer.
T-cell-mediated immunity by selective constitutive 2020;19(1):145.
and inducible expression of PD-L1. Clin Cancer Res. doi: 10.1186/s12943-020-01258-7
2016;22(14):3571-3581.
115. Odate S, Veschi V, Yan S, Lam N, Woessner R, Thiele CJ.
doi: 10.1158/1078-0432.Ccr-15-2665
Inhibition of STAT3 with the generation 2.5 antisense
105. Wu A, Wei J, Kong LY, et al. Glioma cancer stem cells oligonucleotide, AZD9150, decreases neuroblastoma
induce immunosuppressive macrophages/microglia. tumorigenicity and increases chemosensitivity. Clin
Neuro Oncol. 2010;12(11):1113-1125. Cancer Res. 2017;23(7):1771-1784.
doi: 10.1093/neuonc/noq082 doi: 10.1158/1078-0432.Ccr-16-1317
106. Wei J, Barr J, Kong LY, et al. Glioblastoma cancer-initiating 116. Shastri A, Choudhary G, Teixeira M, et al. Antisense
cells inhibit T-cell proliferation and effector responses by STAT3 inhibitor decreases viability of myelodysplastic and
the signal transducers and activators of transcription 3 leukemic stem cells. J Clin Invest. 2018;128(12):5479-5488.
pathway. Mol Cancer Ther. 2010;9(1):67-78.
doi: 10.1172/jci120156
doi: 10.1158/1535-7163.Mct-09-0734
117. Paunovska K, Loughrey D, Dahlman JE. Drug
107. Salomé B, Sfakianos JP, Ranti D, et al. NKG2A and HLA-E delivery systems for RNA therapeutics. Nat Rev Genet.
define an alternative immune checkpoint axis in bladder 2022;23(5):265-280.
cancer. Cancer Cell. 2022;40(9):1027-1043.e9.
doi: 10.1038/s41576-021-00439-4
doi: 10.1016/j.ccell.2022.08.005
118. Saadi M, Karkhah A, Pourabdolhossein F, Ataie
108. Herbst RS, Majem M, Barlesi F, et al. COAST: An open- A, Monif M, Nouri HR. Involvement of NLRC4
label, phase II, multidrug platform study of durvalumab inflammasome through caspase-1 and IL-1β augments
alone or in combination with oleclumab or monalizumab neuroinflammation and contributes to memory
in patients with unresectable, stage III non-small-cell lung impairment in an experimental model of Alzheimer’s like
cancer. J Clin Oncol. 2022;40(29):3383-3393. disease. Brain Res Bull. 2020;154:81-90.
doi: 10.1200/jco.22.00227 doi: 10.1016/j.brainresbull.2019.10.010
109. Li C, Yang Z, Du Y, et al. BCMab1, a monoclonal antibody 119. Yang Z, Wang H, Zhang N, et al. Chaetocin abrogates
against aberrantly glycosylated integrin α3β1, has potent the self-renewal of bladder cancer stem cells via the
antitumor activity of bladder cancer in vivo. Clin Cancer suppression of the KMT1A-GATA3-STAT3 circuit. Front
Res. 2014;20(15):4001-4013. Cell Dev Biol. 2020;8:424.
doi: 10.1158/1078-0432.Ccr-13-3397 doi: 10.3389/fcell.2020.00424

Volume 1 Issue 1 (2024) 48 doi: 10.36922/mi.2377